Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | GAK | O14976 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.42 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 12/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24010272 | 0.93 | LRRK2 (0.38) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL24010184 | 0.92 | KDR (0.49) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL24006251 | 0.85 | KDR (0.46) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999408 | 0.85 | MAPKAPK2 (0.49) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL24010185 | 0.85 | KDR (0.41) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL24010186 | 0.85 | MAPKAPK2 (0.44) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL24006229 | 0.84 | KDR (0.52) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999406 | 0.80 | MAPKAPK2 (0.52) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL23999401 | 0.79 | MAPKAPK2 (0.51) | MAPKAPK2GAKRIPK2COQ8ANLK | |
| SCHEMBL25827896 | 0.79 | GSK3B (0.40) | KDRBRAFKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | MAPKAPK2 136/4885GAK 493/4885RIPK2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.